Skip to main content

Table 2 Treatment at the end of follow-up (death or the end of the study)

From: Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents

Treatment

Number (%) of patients

All

Group 1

Group 2

Group 3

Group 4

Epoprostenol*

22 (54)

13 (32)

9 (22)

0 (0)

0 (0)

ERA†

9 (22)

1 (2)

0 (0)

4 (10)

4 (10)

PDE5I

14 (34)

3 (7)

1 (2)

4 (10)

6 (15)

Beraprost

3 (7)

0 (0)

0 (0)

1 (2)

2 (4)

  1. Variables are number (%) of patients. ERA: endothelin receptor antagonist, PDE5I: phosphodiesterase 5 inhibitor. Some patients received more than one of the drugs. *p < 0.001, †p = 0.035.
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us